ATAI Life Sciences N.V. (ATAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATAI POWR Grades
- Growth is the dimension where ATAI ranks best; there it ranks ahead of 82.08% of US stocks.
- ATAI's strongest trending metric is Stability; it's been moving down over the last 178 days.
- ATAI ranks lowest in Stability; there it ranks in the 10th percentile.
ATAI Stock Summary
- ATAI's price/sales ratio is 477.28; that's higher than the P/S ratio of 99.05% of US stocks.
- With a year-over-year growth in debt of 1,690.1%, ATAI LIFE SCIENCES NV's debt growth rate surpasses 98.64% of about US stocks.
- As for revenue growth, note that ATAI's revenue has grown -97.92% over the past 12 months; that beats the revenue growth of just 0.84% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to ATAI LIFE SCIENCES NV, a group of peers worth examining would be NRGV, IONQ, QNST, SEER, and CWAN.
- ATAI's SEC filings can be seen here. And to visit ATAI LIFE SCIENCES NV's official web site, go to www.atai.life.
ATAI Valuation Summary
- ATAI's price/sales ratio is 477.4; this is 10057.45% higher than that of the median Healthcare stock.
- ATAI's price/earnings ratio has moved up 16.4 over the prior 21 months.
Below are key valuation metrics over time for ATAI.
ATAI Price Target
For more insight on analysts targets of ATAI, see our ATAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$29.10||Average Broker Recommendation||1.38 (Strong Buy)|
ATAI Stock Price Chart Interactive Chart >
ATAI Price/Volume Stats
|Current price||$1.19||52-week high||$5.74|
|Prev. close||$1.22||52-week low||$1.14|
|Day high||$1.25||Avg. volume||1,417,178|
|50-day MA||$1.69||Dividend yield||N/A|
|200-day MA||$3.08||Market Cap||197.39M|
ATAI Life Sciences N.V. (ATAI) Company Bio
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Most Popular Stories View All
ATAI Latest News Stream
|Loading, please wait...|
ATAI Latest Social Stream
View Full ATAI Social Stream
Latest ATAI News From Around the Web
Below are the latest news stories about ATAI LIFE SCIENCES NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.
Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts
Atai Life Sciences has just announced 30% job cuts.
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc
The 7 Most Promising Psychedelic Stocks to Buy in February
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector.
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
HC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ: ATAI) from $50 to $20 to reflect recent adverse outcomes in programs such as PCN-101 in treatment-resistant depression and KUR-101 in opioid use disorder. Most recently, Atai Life Sciences-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants' depression rating scale score at 24 hours co
ATAI Price Returns
Loading social stream, please wait...